Killing the Killers: Natural Killer Cell Therapy Targeting Glioma Stem Cells in High-Grade Glioma.

in Molecular therapy : the journal of the American Society of Gene Therapy by Poorva Poorva, Jensen Mast, Bihui Cao, Mitesh V Shah, Karen E Pollok, Jia Shen

TLDR

  • The study proposes future directions for improving and clinically advancing these therapies, including overcoming challenges such as the brain-blood barrier and the immunosuppressive tumor microenvironment.

Abstract

High-grade gliomas (HGGs), including glioblastoma (GBM) in adults and diffuse intrinsic pontine glioma (DIPG) in children, are among the most aggressive and deadly brain tumors. A key factor in their resilience is the presence of glioma stem cells (GSCs), which drive tumor initiation, progression, and resistance to treatment. Targeting and eradicating GSCs holds potential for curing both GBM and DIPG. Natural Killer (NK) cells, as part of the innate immune system, naturally recognize and destroy malignant cells. Recent advances in NK cell-based therapies, such as chimeric antigen receptor (CAR)-NK cells, NK cell engagers, and NK cell-derived exosomes, offer promising approaches for treating GBM and DIPG, particularly by addressing the persistence of GSCs. This review highlights these advancements, explores challenges such as the brain-blood barrier and the immunosuppressive tumor microenvironment, and proposes future directions for improving and clinically advancing these NK cell-based therapies for HGGs.

Overview

  • The primary objective is to review the current state of NK cell-based therapies for HGGs, highlighting challenges and proposing future directions for improvement and clinical advancement.

Comparative Analysis & Findings

  • The study identifies challenges in developing these therapies, including the brain-blood barrier and the immunosuppressive tumor microenvironment, which need to be addressed for clinical advancement.

Implications and Future Directions

  • The study aims to contribute to the development of novel and effective therapies for HGGs, improving patient outcomes and quality of life.
Read Full Article